Background: The 12-item Multiple Sclerosis Walking Scale (12-MSWS) is a validated questionnaire which assessed walking function; it has been widely adopted in multiple sclerosis (MS) clinical research. Objective: Identify and validate clinically meaningful 12-MSWS benchmarks in MS. Methods: Cross-sectional study of 159 MS patients permitted identification of clinically meaningful 12-MSWS benchmarks based on their relationship to real-life anchors. Identified 12-MSWS benchmarks were then validated in a second population of 96 subjects using measures of ambulation, cognition, and patient-reported outcomes. Results: 12-MSWS score of 0-24.99 was associated with working outside the home and assistance-free mobility; 25-49.99 was associated with gait disability and difficulty doing housework; 50-74.99 was associated with unemployment, government healthcare, cane use, and difficulty performing instrumental activities of daily living (IADLs); and 75-100 was associated with change in occupation due to walking, mobility impairment requiring bilateral assistance, and inability to perform IADLs. During the validation step, strong linear associations were identified between 12-MSWS benchmarks and other MS-related disability outcome measures, including ambulatory and non-ambulatory measures. Conclusion: We have identified clinically meaningful 12-MSWS benchmarks which define four groups differentiated by increasing levels of mobility impairment and associated loss of functional independence. These data provide insight into how 12-MSWS translate to meaningful functional limitations in MS.
Introduction
Mobility impairment is prevalent among patients with multiple sclerosis (MS) 1 and is often observed early in disease course even at otherwise low degrees of clinical disease burden. 2, 3 Mobility decline in MS is correlated with decreased health-related quality of life and increased indirect costs such as lost work-place productivity. 4 Patient-perceived mobility impairment tends to increase with lengthening duration of disease. 5 Multiple measures exist for the assessment of walking function in MS. 6 The majority of these depend on objective measures of walking times. The Timed 25-Foot Walk (T25FW) is one such measure, and clinically meaningful benchmarks in T25FW performance have been identified-demonstrating associations with occupational changes and disability due to MS, need for assistive devices, loss of independence with activities of daily living, and government income and healthcare assistance. 7, 8 The 12-item Multiple Sclerosis Walking Scale (12-MSWS) is a validated and reliable questionnaire assessing the impact of MS on walking, can be easily administered in a clinical setting, and has been widely adopted in MS clinical research [9] [10] [11] . The 12-MSWS results in a total calculated score range from 12 to 60, which is then transformed into scores ranging from 0 to 100. A higher score is indicative of increased walking impairment. Of the available walking measures in MS, the 12-MSWS is unique as a measure of patientreported perception of ambulatory function.
We hypothesized that, similar to the T25FW, 12-MSWS benchmarks could be identified to indicate significant and meaningful changes in real-world disability.
Methods

Standard protocol approvals, registrations, and patient consent
This study involved a secondary analysis of existing cross-sectional data 7 and identified and validated clinically meaningful 12-MSWS benchmarks as was done for the T25FW. Study protocols were approved by the University of Virginia (Identification Step) and University of Illinois at Peoria (Validation Step) institutional review boards. All participants provided informed written consent.
MS populations
A questionnaire was mailed to all 300 individuals with MS (relapsing or progressive forms) who had available T25FW test available as part of their routine clinical care in the 15 months prior to survey mailing (2/2011). No respondents were having an MS-relapse at time of T25FW measurement. Surveys included general demographic information, as well as validated scales of MS disability and activities of daily living. Respondents provided clinically meaningful information regarding marital status, current employment, instrumental activities of daily living (IADL), 7, 12 and use of walking assistive devices. Surveys also included the 12-MSWS, Patient Determined Disease Steps (PDDS) and Performance Scales (PS), 13, 14 and Beck Depression Inventory-Fast Screen. 15, 16 The mean and median 12-MSWS scores of our population were calculated within all of the real-life anchor categories collected (e.g. married vs divorced, working full time, government healthcare assistance, and IADL independence). Using mean and median 12-MSWS scores, we identified and grouped subjects by candidate benchmarks. We then formed potential benchmark groupings in 10, 20, or 25 increments to determine the proportion of subjects in a real-life anchor category within each candidate benchmark group and the discriminate value of the different incremental groupings.
The benchmark validation step recruited 96 subjects from three area neurologists in mid-2011. All had confirmed MS (relapsing or progressive form) and were without acute relapse at time of study visit. Inclusion criteria were ability to ambulate independently or with an assistive device. Participants completed all testing in a single, 2-hour session, which included the following: Expanded Disability Status Scale (EDSS), objective ambulation testing (T25FW, Timed Up and Go (TUG)), 17 Six Spot Step Test (SSST), 18 Six-Minute Walk Test (6MWT), 3, 19 with associated oxygen cost of walking (O 2 cost), 20,21 a 7.9-m GAITRite electronic mat (CIR Systems Inc., Havertown, PA) for overall gait based on the Functional Ambulation Performance (FAP) score, 22, 23 and cognitive function (3-second Paced Auditory Serial Addition Task (PASAT) and Symbol Digit Modalities Test (SDMT)). 24, 25 Subjective measures included the 12-MSWS, functional limitations portion of the Late-Life Function and Disability Inventory (LL-FDI) 26 and Symptom Inventory (SI). 14 Participants then wore a triaxial accelerometer during the waking hours of a 7-day period to capture freeliving ambulation as counts per day; this metric is a summary indicator of the volume (intensity and duration) of ambulatory physical activity accumulated over the course of the day. Accelerometers were returned through the US Postal Service.
Statistical analysis
Identification step data were analyzed using SAS 9.4 software (SAS Institute Inc., Cary, NC). Descriptive statistics of demographics and real-life anchor 12-MSWS scores were used to identify candidate 12-MSWS performance benchmarks. Candidate 12-MSWS benchmark-defined group differences on real-life anchors and self-report measures were completed using analysis of variance and χ 2 test, as appropriate. During the benchmark validation step using SPSS 19.0 (IBM Corp., Armonk, NY), a second sample of MS participants were stratified by 12-MSWS benchmarks (group 1: 0-24.99, group 2: 25-49.99, group 3: 50-74.99, group 4: 75-100). We performed analysis of variance with a priori linear contrasts on the different outcomes; the univariate F-ratios, t-values assuming equal and unequal variances, and partial η 2 values were used to examine the presence and magnitude of linear differences in the dependent outcome per 12-MSWS group. Of note, η 2 is analogous with R 2 and reflects variance explained in the outcome variable. 
Results
During the benchmark identification step, 169 completed surveys were returned of the 300 sent, a 56.3% response rate. This response rate is similar to other mail surveys in the medical literature. 27 For analyses, we included only those subjects with a T25FW recorded within 6 months of survey completion, which resulted in exclusion of eight subjects. Two additional subjects were excluded, one for a T25FW of >2 minutes and one who was no longer walking at the time of the survey. Ultimately, 159 MS subjects we utilized for analyses. Survey responders had similar T25FW performance compared to survey non-responders (mean 8.2 ± 7.89 seconds (range, 3.25-65 seconds) and mean 8.55 ± 9.79 seconds (range, 3.12-104 seconds), respectively). 7 Of the 159 subjects, 68% were women with an average age of 48 ± 12.6 years. Additional study subject population demographics are detailed in Table 1 . For survey responders, the 12-MSWS median was 43.8 and 45% were employed, either outside or within the home. In all, 37% self-identified as disabled. Only 37.8% of all responders were working full time (60/159 subjects) and 44% reported a change in occupational status due to MS. Potential 12-MSWS benchmarks were identified using the median 12-MSWS across real-life anchors (Table 2; Figure 1 ). Review of the median scores within real-life anchor categories was investigated for information regarding both extreme cut-points (lowest and highest ends of scores), overlapping values across similar anchor groups, or differences between levels of disability within single anchor. For example, 12-MSWS median < 10 was identified as a distinct cut point. The only anchors with a median score in the 0-25 range were PDDS and all Performance Scores = 0 and full independence with several IADLs. Alternatively, a median score of 60-65 was found across several anchors-for example, disabled, change in occupation due to MS, government healthcare assistance, and cane use. Next, we grouped subjects using different increments, for example, 10 [0-9.99, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] >50% now report mild-moderate hand impairment and 30%-57% report mild-moderate disability in vision, fatigue, cognitive, bladder/bowel, sensory, spasticity, pain, depression, and tremor/loss of coordination domains on PS. In the most impaired mobility group, 12-MSWS 75-100, 20% report either severe or total hand disability and again we see a notable across the board increase in disability across other domains in this group with 20%-50% reporting severe total disability in vision, fatigue, bladder/ bowel, sensory, spasticity, pain, depression, and tremor/loss of coordination domains on PS.
To confirm and validate these 12-MSWS benchmarks, we conducted additional analysis in a second, independent MS sample recruited from a regionally different institution. During the benchmark validation step, 96 subjects with MS completed the assessment. This was a separate cohort from the first 169. Average age was 52.7 and the median EDSS score was 4.5 with a range between 2 and 6.5. The median 12-MSWS was 50.0 with a mean of 44. We then tested all measures for expected linear differences/trends across groupings of 12-MSWS scores ( Table 4 ). There were statistically significant linear trends for stratified 12-MSWS benchmarks across both objective and subjective measures: 6MWT (p < 0.001), TUG (p < 0.001), SSST (p < 0.001), T25FW (p < 0.001), accelerometer counts per day (p < 0.001) and steps per day (p < 0.001), FAP score from the GAITRite (p < 0.001), SDMT (p < 0.001), LL-FDI (p < 0.001), and SI (p < 0.001). Mean scores for these benchmarks are reported in Table 5 . The linear trends indicate a linear, systematic change in the outcomes per level of 12-MSWS benchmark.
Discussion
The impact of mobility impairment on employment and functional status in MS has been well characterized. 28 The 12-MSWS is a validated patient-reported outcome (PRO) measure of walking impairment in MS, and translating these PROs typically used in research settings to clinically meaningful benchmarks can be a useful way to classify an individual's disability and monitor its accrual over time. Our study approach and resultant data add to the available literature regarding clinically meaningful benchmarks in MS outcome measures, which was previously limited to only objective measures. 7, 8 12-MSWS scores of 50-74.99 and >75 appear to represent a substantial shift in functional independence. Patients with 12-MSWS of 50-74.99 are more likely to have employment changes related to MS, receive government healthcare assistance, experience cognitive difficulty and fatigue, and require a cane for mobility. Across all groups, increases in 12-MSWS were associated with more difficulty completing IADLs and increased likelihood of receiving disability benefits. Ambulatory and functional limitations further increase beyond an 12-MSWS of 75, as these patients are more likely to require bilateral assistance, a walker, or wheelchair for ambulation and are more likely to be unable to complete their own IADLs. Interestingly, our data also demonstrate that increasing mobility difficulty is associated with increasingly severe disability across multiple other domains, demonstrating our clinical experience that disability is not domain specific and comprehensive measurement/assessment is needed to capture the spectrum of MS-related disability. These results also demonstrate that increasing disability in one domain is associated with increasing disability across other domains.
The validation step in our study further confirmed the strong linear association between levels of 12-MSWS benchmarks and other MS-related disability measures, including objective ambulatory measures (T25FW, TUG, 6MW, SSST, FAP, and accelerometer data) and non-ambulatory measures (SDMT, LL-FDI, and SI). Regarding cognitive measures, significant differences were seen with increased 12-MSWS benchmarks and SDMT, but not PASAT, scores, yet these differences were small in magnitude. Such results suggest some degree of specificity of the 12-MSWS benchmarks for MS-related mobility disability that is relatively unaffected by general cognitive impairment based on SDMT and PASAT scores. It is important to note that we have identified and validated cross-sectional benchmarks, and we have not demonstrated that a 25-point "change" in the 12-MSWS represents the minimal clinically important difference (MCID) and/ or detectable change; the MCID for the 12-MSWS has been reported to be 4-22 depending on the statistical approach and population studied. 11, 29, 30 While this cross-sectional approach is one limitation to our study, we believe that these 12-MSWS benchmarks are a meaningful way to describe and understand what a sample score means for real-world consequences. This should not be confused with the MCID value, which reflects a meaningful change brought about by an intervention or change over time.
It is important to note that both of our study populations where from a US sample, and therefore, some of the anchors used (e.g. government healthcare) may not translate to other non-US populations. In addition, choices of when to leave the work force and/or work from home are likely also shaped by work flexibility and opportunities that may have US biased elements. Finally, the 12-MSWS was designed from and for an MS population, and the tool has been applied to other neurologic populations (e.g. stroke). 31 Caution should be taken when applying these benchmarks to non-MS patients, due to important differences in tempo and pattern of disability progression in neurologic disease (e.g. MS vs stroke).
There has been increasing emphasis on PROs recently, so PROs have been included as secondary or tertiary endpoints in recent clinical trials of disease-modifying therapies for MS. PROs are obviously important, but at times, there may be a seeming discordance between clinical data and patient-reported perceptions. One potential explanation for this disconnect may be the presence of comorbidities; indeed, a recent study suggested that the impact of physical disability and that of depression were almost identical on another Health Related Quality of Life PRO (Health Utilities Index Mark 3) in people with MS. 32 Given this, it is useful to be able to correlate PRO changes with meaningful clinical benchmarks when interpreting the implications of PRO endpoints in clinical trials and clinical practice. Furthermore, PROs will also have medico-economic implications as healthcare reimbursements, at least in the United States, shift from a "fee for service" paradigm to a Merit-Based Incentive Payment System (MIPS) based on the value and quality of the service provided. The identification of benchmarks is important for helping research and clinicians interpret 12-MSWS scores based on standards with associated real-world relevance and may suggest that this PRO is appropriate to include as a quality measure for MIPS which would directly impact practicing neurologists. However, we do not anticipate that the 12-MSWS would be used in substitution to the neurologic exam, but rather augment the objective data of an exam. The added value of these benchmarks allows the 12-MSWS data provided by the individual patient to then be contextualized into a larger framework of population-based MS disability. Our data provide this framework with new insight into how categories of mobility impairment on the 12-MSWS may translate to other, more broad functional limitations in MS.
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